1174. Phase 2 STRIVE Clinical Trial of Rezafungin for Treatment of Candidemia and/or Invasive Candidiasis Demonstrates Consistent Trough Concentrations Across Diverse Patient Popul...

por Flanagan, Shawn, Rubino, Christopher M, Sandison, Taylor
Publicado 2020

Absence of Clinically Meaningful Drug-Drug Interactions with Rezafungin: Outcome of Investigations

por Flanagan, Shawn, Walker, Helen, Ong, Voon, Sandison, Taylor
Publicado 2023

Individual donation nucleic acid technology testing to minimize human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus transfusion transmitted infections

por Shyamala, Venkatakrishna, Sandison, Taylor G., Holmberg, Jerry A.
Publicado 2014

Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults

por Sandison, Taylor, Ong, Voon, Lee, Jonathan, Thye, Dirk
Publicado 2017

1286. Pharmacokinetics, Excretion, and Mass Balance of [(14)C]-Rezafungin Following Intravenous (IV) Administration in Healthy Adults

por Ong, Voon, Flanagan, Shawn, Sandison, Taylor, Wills, Sarah
Publicado 2020

262 Effect of NSAID/Corticosteroid Use on the Efficacy of Tedizolid in Acute Bacterial Skin and Skin Structure Infections: Pooled Data From the Phase 3 ESTABLISH-1 and ESTABLISH-2...

por Sandison, Taylor, De Anda, Carisa, Das, Anita, Prokocimer, Philippe
Publicado 2014

Metabolism, Excretion, and Mass Balance of [(14)C]-Rezafungin in Animals and Humans

por Ong, Voon, Wills, Sarah, Watson, Deborah, Sandison, Taylor, Flanagan, Shawn
Publicado 2022

P28 Rezafungin efficacy and safety in immunocompromised patients: sub-analyses of the Phase 3 trial in treatment of candidaemia and invasive candidiasis

por Sandison, Taylor, Ramos-Martinez, Antonio, Kim, Young Keun, Chai, Louis, Slavin, Monica
Publicado 2023

2389. Effect of Rezafungin on QT Interval in Healthy Subjects

por Flanagan, Shawn, Goodman, Daniel B, Rao, Pallavi, Jandourek, Alena, O’Reilly, Terry, Sandison, Taylor
Publicado 2018

A phase I randomized, double‐blind, single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjects

por Gu, Kenan, Ruff, Dennis, Key, Cassandra, Thompson, Marissa, Jiang, Shoshanna, Sandison, Taylor, Flanagan, Shawn
Publicado 2022

P27 Rezafungin treatment of candidaemia and invasive candidiasis: outcomes stratified by baseline renal function—analysis of the Phase 2 + Phase 3 trials

por Sandison, Taylor, Vazquez, Jose A, Honore, Patrick M, Soriano, Alex, Horcajada, Juan P, Slavin, Monica
Publicado 2023

637. Outcomes by Body Mass Index (BMI) in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin

por Vazquez, Jose A, Flanagan, Shawn, Pappas, Peter, Thompson, George R, Sandison, Taylor, Honore, Patrick M
Publicado 2020

982. Effect of Hepatic Impairment on the Safety and Pharmacokinetics of Rezafungin

por Huguet, Jade, Ong, Voon, Sandison, Taylor, Melara, Rebeca M, Marbury, Thomas C, Jandourek, Alena, Flanagan, Shawn
Publicado 2021

1284. Outcomes by Baseline Pathogens and Susceptibility in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Cas...

por Thompson, George R, Horcajada, Juan P, Locke, Jeffrey B, Viani, Rolando, Pappas, Peter, Ghannoum, Mahmoud, Sandison, Taylor, Soriano, Alex
Publicado 2020

1390. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Rezafungin (RZF) Dose Selection in Treatment of Candida

por Lakota, Elizabeth A, Ganesan, Harish, Flanagan, Shawn, Ong, Voon, Sandison, Taylor, Bhavnani, Sujata M, Rubino, Christopher M, Ambrose, Paul G
Publicado 2018

1718. Rezafungin Clinical Safety and Efficacy in Patients With Candidemia and/or Invasive Candidiasis in the Randomized, Double-Blind, Multicenter, Phase 2 STRIVE Study

por Thompson, George R, Vazquez, Jose, Soriano, Alex, Skoutelis, Athanasios, Ostrosky-Zeichner, Luis, Mena, Karen, Navalta, Laura, Sandison, Taylor, Pappas, Peter
Publicado 2018

Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata

por Bader, Justin C., Lakota, Elizabeth A., Flanagan, Shawn, Ong, Voon, Sandison, Taylor, Rubino, Christopher M., Bhavnani, Sujata M., Ambrose, Paul G.
Publicado 2018

Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children

por Katrak, Shereen, Gasasira, Anne, Arinaitwe, Emmanuel, Kakuru, Abel, Wanzira, Humphrey, Bigira, Victor, Sandison, Taylor G, Homsy, Jaco, Tappero, Jordan W, Kamya, Moses R, Dorsey, Grant
Publicado 2009

The association between malnutrition and the incidence of malaria among young HIV-infected and -uninfected Ugandan children: a prospective study

por Arinaitwe, Emmanuel, Gasasira, Anne, Verret, Wendy, Homsy, Jaco, Wanzira, Humphrey, Kakuru, Abel, Sandison, Taylor G, Young, Sera, Tappero, Jordan W, Kamya, Moses R, Dorsey, Grant
Publicado 2012

Protective efficacy of co-trimoxazole prophylaxis against malaria in HIV exposed children in rural Uganda: a randomised clinical trial

por Sandison, Taylor G, Homsy, Jaco, Arinaitwe, Emmanuel, Wanzira, Humphrey, Kakuru, Abel, Bigira, Victor, Kalamya, Julius, Vora, Neil, Kublin, James, Kamya, Moses R, Dorsey, Grant, Tappero, Jordan W
Publicado 2011